Myriad Genetics, Inc.

University of Utah Research Foundation

Steven Stone

Alexander Gutin

Julia Reid

Susanne Wagner

Alexander Kamb

Ping Jiang

Victor Abkevich

Donna Shattuck

Deanna L Russell

Steven Hunt

Sean V Tavtigian

Biomarkers and methods using the biomarkers for classifying cancer in a patient (e.g., predicting the risk of cancer-specific death or cancer recurrence) are provided.

Gene signatures for cancer prognosis

Biomarkers and methods using the biomarkers for the prediction of the recurrence risk of cancer in a patient are provided.

Cancer Biomarkers

Cancer biomarkers

Biomarkers and methods using the biomarkers for molecular detection and classification of disease and, particularly, molecular markers for cancer diagnosis and prognosis and methods of use thereof are provided.

Gene signatures for cancer diagnosis and prognosis

The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human obesity and diabetes predisposing gene, specifically the TBC1D1 gene, some mutant alleles of which cause susceptibility to obesity and/or diabetes. More specifically, the invention relates to germline mutations in the TBC1D1 gene and their use in the diagnosis of predisposition to obesity and diabetes. Finally, the invention relates to the screening of the TBC1D1 gene for mutations/alterations, which are useful for diagnosing the predisposition to obesity.

Obesity gene and use thereof

The present invention relates to the Multiple Tumor Suppressor (MTS) genes in mice, their expression products, and their homology to the human MTS genes. The human MTS genes are involved in human cancers. The invention is further related to the use of the MTS genes in the therapy, diagnosis and prognosis of human cancer. The invention further relates to mutations in the MTS gene and their use in the diagnosis of predisposition to melanoma, leukemia, astrocytoma, glioblastoma, lymphoma, glioma, Hodgkin's lymphoma, CLL, and cancers of the pancreas, breast, thyroid, ovary, uterus, testis, kidney, stomach and rectum. The invention also relates to the therapy of human cancers which have a mutation in the MTS gene, including gene therapy, protein replacement therapy and protein mimetics. Finally, the invention relates to the screening of drugs for cancer therapy.

Mouse MTS2 gene

Mouse MTSI gene

The present invention is directed to cloning the ends of genes. Traditionally it has been very difficult to recover the 5' end of a gene. The present invention greatly eases this problem. The invention is a variation on RACE and uses a combination of techniques. Specific genes are purified by using three enrichment steps--1) a polymerase chain reaction, 2) a hybrid capture step, and 3) a second polymerase chain reaction. The inclusion of the hybrid capture step results in a greater enrichment than occurs with RACE. The ends of the gene are retained by use of a novel technique of attaching adaptors at the ends of the nucleic. The 5' end of the gene is conserved by preparing a first strand of cDNA and ligating to this an adaptor which is partially double stranded wherein the overhang or single stranded region of the adaptor is degenerate which allows for a fraction of the adaptor population to hybridize with the first strand of cDNA at the 3' end of the cDNA. This hybridization holds the adaptor in conjunction with the cDNA during the ligation step thereby resulting in a highly efficient ligation. The unique portion of the adaptor is used to design an oligomer to prime the second strand synthesis. None of the 5' sequence is lost in this method thereby allowing for a greater possibility of recovering the extreme 5' end of the gene.

Growing community of inventors

Salt Lake City, UT, United States of America

Steven Stone